CN101195025A - 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 - Google Patents
胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 Download PDFInfo
- Publication number
- CN101195025A CN101195025A CNA2007101700684A CN200710170068A CN101195025A CN 101195025 A CN101195025 A CN 101195025A CN A2007101700684 A CNA2007101700684 A CN A2007101700684A CN 200710170068 A CN200710170068 A CN 200710170068A CN 101195025 A CN101195025 A CN 101195025A
- Authority
- CN
- China
- Prior art keywords
- medicine
- eyes
- application
- actin
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 title abstract description 73
- 102100035000 Thymosin beta-4 Human genes 0.000 title abstract description 4
- 108010079996 thymosin beta(4) Proteins 0.000 title abstract 3
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 18
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 25
- 206010013774 Dry eye Diseases 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 20
- 102000007469 Actins Human genes 0.000 claims description 19
- 108010085238 Actins Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 230000007850 degeneration Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000009919 sequestration Effects 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- QQKKFVXSQXUHPI-NBVRZTHBSA-N Acidissiminol epoxide Chemical compound O1C(C)(C)C1CC(O)C(/C)=C/COC(C=C1)=CC=C1CCNC(=O)C1=CC=CC=C1 QQKKFVXSQXUHPI-NBVRZTHBSA-N 0.000 claims description 4
- 101710138529 Depactin Proteins 0.000 claims description 4
- FCHAMFUEENBIDH-UHFFFAOYSA-N Severin Natural products CC1CCC2C(C)C3CCC4(O)C(CC5C4CC(O)C6CC(CCC56C)OC(=O)C)C3CN2C1 FCHAMFUEENBIDH-UHFFFAOYSA-N 0.000 claims description 4
- 229940087051 fragmin Drugs 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 claims description 3
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 claims description 3
- 101710193892 Actobindin Proteins 0.000 claims description 3
- 102000002151 Microfilament Proteins Human genes 0.000 claims description 3
- 108010040897 Microfilament Proteins Proteins 0.000 claims description 3
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims description 3
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 238000001935 peptisation Methods 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000008521 reorganization Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 101710202766 Thymosin beta-4 Proteins 0.000 description 58
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 12
- 210000004087 cornea Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000005494 xerophthalmia Diseases 0.000 description 9
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000013275 Somatomedins Human genes 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004175 meibomian gland Anatomy 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010027137 Meibomianitis Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000644420 Aplysia californica Thymosin beta Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000031354 Hyphema Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- -1 antibiotic Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27564501P | 2001-03-15 | 2001-03-15 | |
| US60/275,645 | 2001-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028059174A Division CN100360174C (zh) | 2001-03-15 | 2002-03-14 | 胸腺素β4(Tβ4)、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101195025A true CN101195025A (zh) | 2008-06-11 |
Family
ID=23053251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101700684A Pending CN101195025A (zh) | 2001-03-15 | 2002-03-14 | 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 |
| CNB028059174A Expired - Fee Related CN100360174C (zh) | 2001-03-15 | 2002-03-14 | 胸腺素β4(Tβ4)、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028059174A Expired - Fee Related CN100360174C (zh) | 2001-03-15 | 2002-03-14 | 胸腺素β4(Tβ4)、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040131626A1 (enExample) |
| EP (1) | EP1383529A4 (enExample) |
| JP (2) | JP2005506293A (enExample) |
| CN (2) | CN101195025A (enExample) |
| AU (2) | AU2002255736B2 (enExample) |
| CA (1) | CA2441147A1 (enExample) |
| MX (1) | MXPA03008359A (enExample) |
| WO (1) | WO2002074193A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104220087A (zh) * | 2011-12-12 | 2014-12-17 | 美国伊利诺大学理事会 | 用于治疗核酸相关眼病的组合物及方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006023879A1 (en) * | 2004-08-20 | 2006-03-02 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| WO2006076255A2 (en) * | 2005-01-11 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing microbial eye infection |
| KR20080021782A (ko) * | 2005-06-17 | 2008-03-07 | 리지너크스 바이오 파마소티컬스, 인코포레이티드 | 엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들 및 그 방법 |
| CN100372572C (zh) * | 2005-09-29 | 2008-03-05 | 北京诺思兰德生物技术有限责任公司 | 携带人胸腺素β4基因的重组质粒 |
| US20080132451A1 (en) * | 2006-12-01 | 2008-06-05 | Alcon Manufacturing Ltd. | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease |
| EP2260106A4 (en) * | 2008-03-17 | 2011-04-20 | Regenerx Biopharmaceuticals | IMPROVED BETATHYMOSINFRAGMENTS |
| CN102924573B (zh) * | 2012-11-13 | 2014-07-23 | 兆科药业（广州）有限公司 | 一种肌动蛋白结合肽及其用途 |
| WO2016064078A1 (ko) * | 2014-10-22 | 2016-04-28 | 주식회사 지트리비앤티 | 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형 |
| KR20170021667A (ko) * | 2015-08-18 | 2017-02-28 | 주식회사 지트리비앤티 | 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물 |
| CA3031069A1 (en) * | 2016-07-18 | 2018-01-25 | Regentree, Llc | Methods of treating dry eye syndrome |
| CN106692949B (zh) * | 2016-12-23 | 2022-03-15 | 北京诺思兰德生物技术股份有限公司 | 一种用于治疗眼部疾病的药物及其组合物 |
| KR101910908B1 (ko) * | 2017-06-14 | 2018-10-24 | (주)휴온스 | Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물 |
| CA3083101A1 (en) * | 2017-11-24 | 2019-05-31 | G-Treebnt Co., Ltd. | Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient |
| CN113599371A (zh) * | 2021-09-06 | 2021-11-05 | 郑州大学 | 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| US4543340A (en) * | 1983-04-07 | 1985-09-24 | George Washington University | Radioimmunoassay of thymosin β4 |
| AT401180B (de) * | 1990-08-13 | 1996-07-25 | Biomay Biotech Prod | Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung |
| US6124259A (en) * | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
| US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| US5652209A (en) * | 1994-04-29 | 1997-07-29 | University Of Miami | Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy |
| US6391607B1 (en) * | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| JP3128203B2 (ja) * | 1997-02-10 | 2001-01-29 | 一男 坪田 | 分泌腺細胞とリンパ球との接着阻害剤 |
| GB9806632D0 (en) * | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| EP1100529B2 (en) * | 1998-07-30 | 2010-08-25 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Thymosin beta 4 promotes wound repair |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
-
2002
- 2002-03-14 JP JP2002572907A patent/JP2005506293A/ja active Pending
- 2002-03-14 EP EP02725151A patent/EP1383529A4/en not_active Withdrawn
- 2002-03-14 MX MXPA03008359A patent/MXPA03008359A/es not_active Application Discontinuation
- 2002-03-14 CN CNA2007101700684A patent/CN101195025A/zh active Pending
- 2002-03-14 WO PCT/US2002/007730 patent/WO2002074193A2/en not_active Ceased
- 2002-03-14 CN CNB028059174A patent/CN100360174C/zh not_active Expired - Fee Related
- 2002-03-14 US US10/471,621 patent/US20040131626A1/en not_active Abandoned
- 2002-03-14 CA CA002441147A patent/CA2441147A1/en not_active Abandoned
- 2002-03-14 AU AU2002255736A patent/AU2002255736B2/en not_active Ceased
-
2008
- 2008-12-19 AU AU2008261127A patent/AU2008261127A1/en not_active Abandoned
-
2009
- 2009-05-18 JP JP2009120011A patent/JP2009179638A/ja not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104220087A (zh) * | 2011-12-12 | 2014-12-17 | 美国伊利诺大学理事会 | 用于治疗核酸相关眼病的组合物及方法 |
| US9867871B2 (en) | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| US10328129B2 (en) | 2011-12-12 | 2019-06-25 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| US11376312B2 (en) | 2011-12-12 | 2022-07-05 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005506293A (ja) | 2005-03-03 |
| EP1383529A4 (en) | 2005-06-29 |
| AU2008261127A1 (en) | 2009-01-15 |
| CN100360174C (zh) | 2008-01-09 |
| WO2002074193A2 (en) | 2002-09-26 |
| JP2009179638A (ja) | 2009-08-13 |
| HK1074577A1 (en) | 2005-11-18 |
| CN1638789A (zh) | 2005-07-13 |
| CA2441147A1 (en) | 2002-09-26 |
| AU2002255736B2 (en) | 2006-08-31 |
| US20040131626A1 (en) | 2004-07-08 |
| WO2002074193A3 (en) | 2003-12-04 |
| MXPA03008359A (es) | 2004-10-15 |
| EP1383529A2 (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101195025A (zh) | 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用 | |
| DE60120372T2 (de) | Verwendung von insulin zur behandlung von knorpelkrankheiten | |
| Abdelkader et al. | New therapeutic approaches in the treatment of diabetic keratopathy: a review | |
| US20080182780A1 (en) | Method of Preventing or Reducing Scarring of Human Skin | |
| CN101146547A (zh) | 肌肉生长抑制素（gdf-8）拮抗剂用于增进创伤愈合和防止纤维变性疾病的用途 | |
| US10703787B2 (en) | Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema | |
| CN101549148A (zh) | 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用 | |
| AU2002255736A1 (en) | Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives | |
| Izumi et al. | Involvement of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in corneal fibroblasts during corneal wound healing | |
| US20110020449A1 (en) | Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives | |
| EP1853293B1 (en) | Thymosin beta 4 for treating multiple sclerosis | |
| AU2004308378B2 (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent | |
| AU2006233251B2 (en) | Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives | |
| HK1074577B (en) | THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE | |
| MXPA03010446A (es) | Composiciones farmaceuticas a base de timosina (4 (t(4), analogos, isorformas y otros derivados para el tratamiento de epidermolisis vesicular hereditaria e indicaciones dermatologicas asociadas, y metodos para esto. | |
| HK1118017A (en) | THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE | |
| AU2017205185B2 (en) | Therapeutics for ocular immunoinflammatory diseases | |
| US20230126239A1 (en) | Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration | |
| WO2022204331A1 (en) | Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment | |
| WO2020128616A2 (en) | Methods and compositions for controlling cell migration and proliferation | |
| WO2006076255A2 (en) | Method of treating or preventing microbial eye infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1118017 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080611 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1118017 Country of ref document: HK |